Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No treatment given.
- Who it may be relevant to
- Registry conditions: Medullary Thyroid Carcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
Interventions
- Other No treatment given
No treatment given
Primary outcome measures
- Time to first occurence of Medullary Thyroid Carcinoma (MTC) [Time frame: From day 1 up to 15 years]
Eligibility criteria
Inclusion criteria
- 18 years or older during the year of index (date of qualifying medication)
- In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
- ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
- No evidence of cohort qualifying medication during 12-month before the index date
- Reside in the US, including the District of Columbia (DC) during the study period
- No missing values for year of birth
Exclusion criteria
- Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- IQVIA — Parsippany
Identifiers
NCT: NCT07713901 · NN2211-8841 · U1111-1341-5652